Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioInvent, Audiocast, Q3'26

By Inderes10/29/2026, 2:00 PM
BioInvent International

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin Welsch
00:01 - 11:16

Yes. Thank you very much. And welcome everybody to BioInvent's Q3 presentation and report. I will start the presentation. I am Martin Welsch, the CEO. I would like to start with the events in the third quarter. So BI-1808, which is our leading value driver, has gotten a lot of attention. We received FDA Fast Track Designation for the treatment of recurrent ovarian cancer. And then, we had an abstract from modest to meaningful in platinum-resistant ovarian cancer that was accepted for poster presentation at ESMO. I think we will return to the data in more detail. And then we also published two scientific papers in peer-reviewed journals. One was in Cancer Research that was highlighting the mode of action. And then we had another publication just a little bit more than a week ago. But I will come back to that later, but there was one presentation in the third quarter that specifically highlighted FcγRIIB and our BI-1206 program. So then, events after the end of the period. So the board of directors, as we announced yesterday evening, has decided to carry out a rights issue of approximately SEK 430 million, which is gross before issue costs, of which SEK 350 million is covered by subscription commitments and guarantee undertakings. And of course, this is still subject to approval at the extraordinary general meeting, for which we also called yesterday evening. We will adjust the organization to support the prioritized clinical programs. First, BI-1808. Number 2, BI-1206, and I will come back to that later throughout my presentation. BI-1808 and KEYTRUDA, we have shown the latest data at ESMO. They induce durable responses in heavily pretreated platinum-resistant ovarian cancer. And the poster was granted the best poster award in the investigational immunotherapy section. And basically the data is repeating what we have shown at ASCO, but just in a higher number of patients. Then we had to announce that Stefan Ericsson, our CFO, will retire in 2027. Stefan has been with the company for roughly 30 years. He is going into his well-deserved retirement. But we will do that in a very structured way so that there will be no loose ends. Stefan has also agreed to support and help us in this transition. And that was what I mentioned on the first slide. We had first-in-human BI-1808 data published in Clinical Cancer Research just over a week ago. So basically two presentations, two publications covering BI-1808, which is a completely new and unique mode of action. And we are actually the first ones developing this mode of action. So a little bit more details regarding the financing and the organization, as already mentioned, we have considered all options and, in the end, decided to proceed with this rights issue. And we might discuss that also in more detail during the Q&A section. That is targeting SEK 430 million. This is gross before issue costs. As I mentioned previously, SEK 350 million will be covered by subscription commitments and guarantee undertakings. And of course, this has to be approved during an EGM, which will happen on December 1st. As I already mentioned in my introduction. So the organization also will be adjusted. We are considering a workforce reduction of up to 20 FTEs, while maintaining our focus on BI-1808 as our top priority and BI-1206 as our second, and I have already mentioned Stefan Ericsson's retirement. And then I think also something that is really interesting. Dharminder Chahal has been nominated to return as a board member. Of course, this is also subject to approval at the AGM and clearly shows the very strong support that we have from Van Herk, then a little bit more on the data. So this slide summarizes the data that we have just shown at ESMO. As I said earlier, it is a repeat of the data, but with a higher number of patients. So a very nice, strong objective response with one complete response and seven partial responses, along with a nice disease control rate of 53%. And several patients are stable. More than ten months. Six patients are still on treatment at the cutoff in September. We had less than 5% treatment-related discontinuation out of 81 solid tumor patients, which I think is very important because with most of the other modern treatments, you have a much higher treatment-related discontinuation, which of course is not good for the patients. What is discussed a lot is the progression-free survival. And you can see the numbers below. So median progression-free survival as per iRECIST is 10.3 months, and that is probably the most fair consideration because RECIST is really made for chemotherapeutic agents or small molecule compounds, but it is still 4.1. And then as a comparison, pembrolizumab alone in the KEYNOTE-100 is 2.1. And also to mention here. So the patient population that we are treating is heavily pretreated platinum-resistant ovarian cancer, with a median of four prior lines, which is a patient population that is very unresponsive; iRECIST captures delayed responses. The 2.1 month figure is from a different study. That is an indirect comparison. And then the duration of response is not bad. The median follow-up is 11.6 months. Overall, it is a strong data set that we presented at ASCO for BI-1808, and we will share a little bit more on the data here. We show a response in a setting where others have previously failed to deliver. When you look at the objective response rate on the left-hand side, you see the combination is 24%, pembrolizumab alone is 8%, and BI-1808 alone is 6%. So you can see that even as a single agent in recurrent ovarian cancer, BI-1808 behaves very much like pembrolizumab. And that is what we have always said. So when we talk to the outside world, we basically say we have the next version of KEYTRUDA, the next new immuno-oncology mechanism on the right hand side. I do not have the time today to go through this in detail, but this is the very good safety profile that we have. And this is actually quite impressive, considering the heavy pretreatment history. Okay, so what are the next steps? First of all, we have FDA Fast Track Designation for BI-1808 in ovarian cancer that was granted in early August 2026. But we have it also for relapsed or refractory mycosis fungoides and Sézary syndrome CTCL. And that reflects the high unmet medical need. We received the best poster award for the ovarian cancer data at ESMO in the investigational immunotherapy section, and the phase one data and MOA were published. I mentioned that already. Clinical Cancer Research published the phase one data and the mechanism of action, which is very positive. And also additional validation. The next step is the phase 1/2a part C, which is about to start in Q1 2027. And there, we will have three randomized arms with 20 patients each. And then. BI-1808 is being tested in two different concentrations: 1000 mg and 500 mg. The control arm will be pembrolizumab combined with weekly paclitaxel, plus or minus bevacizumab. We expect the first data in the second half of 2027. And that should be very interesting. And that is the data that actually corporates as well as large investors are happy to see and want to see. Okay. Then the expected milestones ahead and our focus. In H1 2027, we will start the study that I just mentioned, the part C, which is the most important value inflection point for the company. Then we will complete the Phase 2a dose optimization for BI-1808 as a monotherapy in CTCL. I would also like to remind everybody. So, this is obviously another strong validator of BI-1808. The data that we have actually positions BI-1808 in the front line as a single agent to treat CTCL. And then last but not least, we are also waiting for the first readout of BI-1206 plus KEYTRUDA in first-line non-small cell lung cancer (NSCLC) and uveal melanoma. Then, during the second half of next year, we expect the first data from the BI-1808 triplet study in ovarian cancer, followed by a potential start of the BI-1206 phase 2b trial, pending data and partnering. We have a clear goal and have now engaged with an external party to help us push potential partnering around BI-1206, but also initiate discussions around 1808. BI-1808. So the focus is very clear. So two targets are TNFR2 and FcγRIIB. And also to highlight this again. So those are first-in-class targets. We are the ones developing those targets in oncology at the moment. And that is always a little bit more difficult because you do not have anything that you can get guidance from. BI-1808 is the current priority. And with the planned rights issue, we aim to take BI-1808 into these randomized and potentially pivotal studies while continuing to develop. BI-1206 with a partner. I think I hand over from here to Stefan, and I will just flip to the next slide. Go ahead, Stefan.

Stefan Ericsson
11:16 - 15:15

Thanks, Martin. I will present the financial overview for Q3 and the nine-month period, January to September. All amounts are in millions unless otherwise mentioned. Net sales were 10.8 million SEK in Q3 2026, compared to 3.3 million SEK in Q3 2025. That is 7.5 million higher in Q3 2026. The increase is related to? The production of antibodies for customers was higher in 2026. Net sales for January to September 2026 were 37 million for the same period. In 2025, it was 224 million. That is a decrease of 187 million. The decrease is mainly related to the fact that in 2025, BioInvent received a $20 million payment when Soma Royalty acquired future rights for mesa. Prior to that, a $1 million milestone was received in the collaboration. In 2026, we received a €1 million milestone from Bayer, and production of antibodies for customers was 3 million higher in 2026. Operating costs decreased from 137 million SEK in Q3 2025 to 131 million SEK in Q3 2026. That is a decrease of 6 million. We had quite high costs in BI-1808 and higher costs in BI-1206, and significantly lower costs in BI-1607 and BI-1910, and we had somewhat lower personnel costs for January to September. The decrease in operating costs was 42 million, from 446 million in 2025 to 404 million in 2026. We had significantly higher costs for BI-1808 and significantly lower costs for BI-1910 and BI-1607, and we had lower personnel costs in 2026. The result for Q3 2026 was -119 million SEK, and the result for January to September 2026 was -361 million SEK. Liquid funds and current investments at the end of September 2026 amounted to. In total, 225 million. Please. Next slide. And regarding the rights issue. We will get 430 million in gross proceeds if there is a full subscription of the rights issue. The rights issue is subject to approval. We will primarily advance BI-1808 in ovarian cancer and secondly, BI-1206 in lung cancer. And we will also advance other priority clinical and preclinical projects. We have received subscription commitments of SEK 80 million from our three largest shareholders. Redmile, Van Herk, and Forbion, as well as other shareholders including Healthinvest. And we have also received guarantee undertakings of 270 million, which in total covers 350 million of the gross proceeds. The expected cash runway extends to the end of 2027. And that is based on the cash position as of September 30th, the 225 million. Our current business plan is based on the completion of the rights issue. This includes the part of the rights issue that is covered by subscription commitments and guarantee undertakings. That amounts to SEK 350 million. If. If we achieve full subscription of the 430 million gross proceeds. This would give us additional financial flexibility for the prioritized clinical programs. The subscription price will be decided around the 25th of November. The EGM will be held on December 1st, and the subscription period is from December 7th to December 21st. Over to you, Martin.

Martin Welsch
15:16 - 15:25

Yes. Thank you, Stefan. And that brings us to the end of our short presentation, and we are happy to take questions. Now.

Operator
15:26 - 15:46

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Arvid Nicator from DNB Carnegie. Please go ahead.

Arvid Nicator
15:48 - 17:06

Hi. Good afternoon and thanks for taking my questions. So first off, I had a question on the ovarian cancer strategy in light of the developments at ESMO. I guess given the overall rapid progress among competitors here with regimens increasingly likely to set a new standard of care and a couple of agents with comparable PFS in slightly different populations, of course, but still nevertheless comparable, and ADCs moving towards earlier treatment lines. Has this changed your assessment of how BI-1808 could fit into the treatment landscape here with the planned triplet combo? And secondly, in light of these competitive developments, what do you believe would constitute a meaningful differentiation in part? And then secondly, on business development, as you said, further development of BI-1206 is dependent on partnering, given the typical lead times involved in doing a deal. How confident are you in progressing towards a partnership in 2027? And is it fair to assume that the upcoming lung cancer data will be pivotal in advancing these important discussions? I'll start there. Thanks.

Martin Welsch
17:07 - 18:41

Okay. Thank you. I will start, and then Andreas, you can chime in. I will start by discussing the clinical data and the positioning of BI-1808 in recurrent ovarian cancer. So I think that we are still steadfast regarding the triplet study. So we assume that we will. And we have done some analysis around that based on our preclinical validation, as well as some modeling; we assume that we can achieve a 3 to 5 months increase in PFS based on the current combination, which is of course pembrolizumab and paclitaxel alone. And we are targeting a 60% objective response rate. And that data should still be very competitive. Also with ADCs. With ADCs, you have to keep in mind that they always have a nice objective response, but the duration remains an issue, but independently from that. So we are not competing directly with ADCs because BI-1808 has a completely different and unique mode of action. So we think we can go ahead of an ADC. We can go after an ADC and potentially also in collaboration or in combination with an ADC. That is something that we are also currently analyzing. And considering, our step into part C is clear and it is a path forward. And before I come to the question, Andreas, do you have anything to add to that?

Andreas
18:42 - 20:39

No, I basically reiterate the fact that we will hear a lot about ADCs in the near future. If you were at ESMO this past week, there are a number of agents in phase three studies or entering phase three studies. However, it is important to note that there are only two payloads. So those drugs are going after basically two types of chemotherapy. We are absolutely not in that ball game. We are in the IO space and in the IO space there is only one approved treatment, and that actually creates an opportunity for BioInvent, because our development path is basically an add-on to that treatment. So as Martin said, you can go before or you can go after, it is not clear. There is no clarity in the field as to what is going to go before or after. And that will depend on how the patient is feeling and how frail the patients are to some of these ADCs, which are quite toxic. They are essentially rough chemotherapy. The field is still dealing with that question. The positioning of BI-1808 is unique in that respect. There is no other agent being developed in the way that we are developing. BI-1808, and that sets BioInvent apart from any other strategy there. So I think that is really important to recognize.

Martin Welsch
20:40 - 22:23

Yeah. Thank you. And then maybe commenting on your second part of the question, which is around business development. As I mentioned earlier in the presentation. So we are focusing more now on BI-1808, finishing up a couple of things around it. 1206, and then really actively looking for a partner, which we have actually been doing for a while. But now we have also teamed up with a very reputable outside organization that is helping us with that. And it is of course always difficult to forecast. The only thing that I can comment here is that we are developing a completely new mode of action. So definitely first-in-class. This might take longer than you hope for because sometimes you have interesting data, but since the mode of action is not known, a lot of partners would like to see a little bit more data. But in any case, regarding BI-1206, our decision is made and there are, of course, two independent streams there. One is in the non-Hodgkin lymphoma setting where we are finishing the follow-up and then summarizing the data. And then we will have some discussions with some companies that we have already talked to before, based then on the final data set. And then, of course, it was also referring to the combination with KEYTRUDA, where we expect data, and I think it is not one or the other. It could be as a package, but already in the non-Hodgkin lymphoma, I think we have some discussions ongoing that are only interested in non-Hodgkin lymphoma, not necessarily the solid tumor cancer and vice versa. So we will see. We will push hard. It is difficult to forecast.

Arvid Nicator
22:26 - 22:29

Great. Thank you so much. I'll jump back in the queue.

Martin Welsch
22:31 - 22:31

Thank you.

Operator
22:33 - 22:38

The next question comes from Clemens Thier from Stifel. Please go ahead. Hi.

Clemens Thier
22:38 - 23:05

Thank you for the presentation and thanks for taking my question. Just one question from my side. Could you specify what is included in your cash runway through 2027? So assuming only the core part, it covers initiation and first readout of part C of BI-1206 in uveal and lung cancer. Is there anything else? What are the next trial initiations included in it? Any color would be great. Thank you.

Martin Welsch
23:06 - 24:30

Yes, I can maybe start and then Stefan Ericsson, you can add to that. So it depends, of course, on how much financing we will raise. Now I am starting from the minimum scenario, which is basically a little bit more than 30 million USD that would cover the initiation of Part C for BI-1808 and would include an interim readout of 30 patients. Since we expect a clear signal, we have already seen a clear signal in the doublet. And we expect also a clear signal there. That should give us a good indication. It would also, of course, cover the finalization of the BI-1206 in non-Hodgkin lymphoma. Basically to finish all the follow-up and data analysis. And then the first readout in first-line non-small cell lung cancer and melanoma. But it would not cover any further work of BI-1206 in that setting. And it would also not cover any additional clinical work for BI-1808 in other solid cancer indications because, as it is not in the public domain yet, we see some interesting other signals that we would like to follow up on, which the funding would also cover. I forgot that when I talked about BI-1808 to round up the CTCL data. But Stefan, maybe you can give a little bit more detail.

Stefan Ericsson
24:31 - 24:49

Yeah. Well, as I said, with the liquid funds we have currently, we are financed until the latter part of Q1 2027. That is in line with what we have said before, and with the secured part of the rights issue completed, we have 430 million in gross proceeds. We are funded until, as Martin said, the end of 2027.

Clemens Thier
24:52 - 24:55

Okay, perfect. Thank you very much.

Martin Welsch
24:56 - 24:56

Thank you.

Operator
25:01 - 25:05

The next question comes from Ken Lee from Pareto. Please go ahead.

Ken Lee
25:07 - 25:53

Hi, Martin. Congratulations. With the securing of the financing. Just two quick questions from me. So with the progression in ovarian cancer, as it is obviously the next inflection point. So how will you handle the use of bevacizumab across different arms? And will the randomization be stratified by that. And the second question is on BI-1206. So there seems to be a bit of a delay in the readout for non-small cell lung cancer and uveal melanoma. And now you are guiding the data readout in the first half of 2027. So could you provide a bit of color on what caused the delay? Is it the enrollment side or follow-up? Thank you.

Martin Welsch
25:54 - 26:42

Yeah. Maybe I will start. And then also Andreas, you can fill in, and I will leave the BI-1808 update completely to Andreas. But on the 1206. 1206. So the delay is basically that we want to mature the data a little bit more. Recruitment was actually quite good. So we have recruited the cohort for uveal melanoma and at least one-third already for the non-small cell lung cancer. And there will be no problem for the first readout as indicated now. And as I said. The main reason for that is that we want to let the data mature a little bit more, and that is related to the mode of action, which is immunomodulatory. And that always needs a little bit more time than other modes of action. Maybe Stefan, you can comment on BI-1808 regarding questions.

Andreas
26:43 - 27:48

Yes. So we will do exactly what Merck did in KEYTRUDA 96. So we will provide pembrolizumab and that will be used at the discretion of the investigator. We anticipate a similar usage to what they had in their study. So that was in the order of 70% of the patients who received bevacizumab. Yes, the arms will be equilibrated for the usage of bevacizumab. So, we are very much in line with KEYNOTE-96. Our. The goal with this study is to demonstrate that BI-1808 actually adds a lot, as Martin mentioned, to the clinical outcome. If you were to be given only pembrolizumab and paclitaxel, plus or minus bevacizumab. So that will be the goal, which is very similar to what they did.

Ken Lee
27:52 - 27:54

Okay. Thank you for taking my questions.

Martin Welsch
27:55 - 27:56

Thank you.

Operator
28:03 - 28:07

The next question comes from Richard Ramstedt from Redeye. Please go ahead.

Richard Ramstedt
28:10 - 28:24

Hello. Good afternoon. I have some questions relating to the rights issue. But let's start with the one on the pipeline. How do you plan to bring BI-1808 in CTCL forward?

Martin Welsch
28:26 - 28:50

So maybe I can start with that, Andrés. And then you can add. The current plan is to finish the ongoing dose optimization. And then get it ready for a potential pivotal study during the second half of next year. But obviously, we will not run that pivotal study on our own. That should be done with a partner.

Richard Ramstedt
28:53 - 28:57

And I guess it would be the same partner as for the ovarian cancer program.

Martin Welsch
28:58 - 29:10

Yes, that would be the ideal situation because otherwise you will not get out the value that is really in the program. Absolutely. Yeah.

Richard Ramstedt
29:12 - 29:28

And then some questions on the rights issue. First, I have a technical question. Is it possible for you to say if the subscription price will be set by a discount or a volume-weighted average price formula?

Stefan Ericsson
29:30 - 29:34

It is a discount. I think it says in the launch. Press release.

Richard Ramstedt
29:36 - 29:45

Yeah, that is what I suspected. And what is the plan for the long-term funding after 2027?

Martin Welsch
29:48 - 30:19

Yeah. So basically, with the minimum amount, we just go to that time point, as you have said. And then of course, the idea is, as we also said in the press release, to combine it with another directed issue that would lead to the full data set in the triplet trial, involving 60 patients. And then, of course, the focus is now even more than it was before. On partnering.

Richard Ramstedt
30:21 - 30:33

A logical follow-up question, I guess, is whether it was difficult to find an investor for a directed issue right now. Then.

Martin Welsch
30:35 - 30:38

Once again, I did not catch that. Sorry, Richard.

Richard Ramstedt
30:39 - 30:46

Was it difficult to find investors for a directed share issue for this funding round?

Martin Welsch
30:47 - 32:37

Yeah. So basically, I have to give a little bit broader perspective here. You know that what we are developing is first-in-class. We are the first ones showing the potential application of BI-1808 or basically the target of TNFR2. The problem with that is the current markets are really mostly focused on best-in-class, not so much on first-in-class. And the interest is high. So we have no problems getting meetings with corporates as well as with large institutional investors. I think the interest is actually getting better, but what they have to see in order to get more comfortable is more data. So I think we took a first step with the ESMO presentation, because one of the questions was, okay, at ASCO, when we have shown what we have shown, that this was in 24 patients. I think the request was to show it in more patients. So this we have done, which is really good. And nothing has changed regarding the quality of the data, even in a larger set of patients. And that is obviously now the main part. So I think there are just one or two patients that still have to be read out, but I think nothing would change there. So that's number one. But then of course, also, since this setting is not the one that you will use in the clinic, the setting will be then the triplet. So I think there is also quite some interest from corporates as well as from large institutions to see the first 20 patients in the triplet setting. And I think that will drive a lot of interest, in case the data comes out as we project. But that is the reason why we had to do what we are doing at the moment.

Richard Ramstedt
32:40 - 32:43

Okay. Good. Thanks. Thanks for answering my questions.

Martin Welsch
32:44 - 32:45

Thank you, Richard.

Operator
32:49 - 32:53

The next question comes from Sebastian van der Schoot from Kempen. Please go ahead.

Sebastian van der Schoot
32:55 - 33:42

Hey guys. Good afternoon and congrats on the extension of the runway to year-end 2027. And also the ESMO presentation. I was particularly wondering regarding the patient population that you are going to enroll for part C, looking at the competitive space with the ADCs that are also moving into earlier lines. Are you thinking about recruiting earlier patients? What are you thinking about the proportion of patients with clear cell carcinoma versus those with high-grade serous adenocarcinoma? What is the delta you are looking for in the part C data? The initial results are expected in H2. Thank you.

Martin Welsch
33:43 - 33:44

Andres.

Andreas
33:47 - 35:50

Yeah. Yes. Hi, Sebastian. So the idea is to reproduce what KEYTRUDA B96 did. This allows me the opportunity to stress the fact that in particular, in ovarian cancer, every line of treatment significantly decreases the overall survival. So when you look at the clinical studies that have been conducted, our patient population, the one presented at ESMO, is a much less responsive patient population. But what I mean by much less is really, really much less responsive. So to see those results in that heavily pretreated patient population is quite significant. What we will do now is we will take the exact same patient population as that of KEYNOTE-B96. So, we are allowing only two previous lines of treatment. And obviously one thing that comes to mind, and I think that may be why you are asking the question, is whether that will cause difficulty in recruitment. Mm-hmm. And enrollment of patients. And what I can tell you is that during the ESMO, I met with a number of different clinicians from different European countries. And they were all very enthusiastic about this and actually requesting that we open their site; one of the clinicians said, I will have no issues putting early patients into your study because of the huge medical need. And again, because when you treat a patient with an ADC, it does not make a lot of sense to follow up with another ADC. That is something that people are failing to recognize, but it is something that is determinant. I think there was another part to your question. Um, yeah. Clear cell versus high grade serous adenocarcinoma.

Sebastian van der Schoot
35:51 - 35:54

Yeah. Clear cell carcinoma versus high-grade serous adenocarcinoma.

Andreas
35:55 - 37:25

Yeah. Right. Clear cell carcinoma is a very interesting indication, which creates an opportunity because, while high-grade serous responds better to chemotherapy, clear cell carcinoma responds very poorly to chemotherapy. In that context, the medical need for that indication is significantly higher than for the others. In that context. Seeing the results that we are seeing in that specific indication is important. This will create an additional opportunity. So our goal is that the study has no restrictions in terms of what patients will come from each subtype. But the idea is to enrich slightly in terms of clear cell, which will probably give us a good understanding of the responses in that specific indication. Because if we continue seeing what we are seeing in that specific patient population, that might create an even clearer and shorter path to approval after this study. So, we will enrich for that patient population, but it is very likely that the large majority will be high-grade serous.

Martin Welsch
37:35 - 37:37

Sebastian, does that address your question?

Sebastian van der Schoot
37:39 - 37:52

Hi guys. Sorry, I was still muted. Regarding the ORR level that you are expecting for the cohort, we will see the initial results in H2 of 2027. What is the benchmark that you are setting for yourself?

Andreas
37:54 - 39:37

I think that the objective response rate, if you look at KEYNOTE-B96, was 53%. I would assume that adding BI-1808 will also contribute. So somewhere around high 50% or 60%, maybe we will get over that bar and that will already be very impressive. However, as I said before, the key endpoint for this, where the battleground will be and you already see it with the ADCs, is PFS. The PFS in the next coming readouts will be essential. So I think that is where we will have a huge increase. And that is where, according to our modeling, we expect at least a three-month addition to PFS. So if you look at what pembrolizumab added to paclitaxel, it was basically less than a month. Our modeling suggests that we will at least add three months to the PFS. And because of the safety of the treatment, it is very likely that we will have an impact on overall survival, despite the fact that we won't be able to measure that in the next study. But substantial additional PFS is the key thing to watch. That is where we think that BI-1808 will differentiate itself from all other agents.

Sebastian van der Schoot
39:40 - 39:41

Great. Thank you very much, guys.

Martin Welsch
39:42 - 39:43

Thank you. Sebastian.

Operator
39:48 - 39:55

There are no more questions this time, so I will hand the conference back to the speakers for any closing comments.

Martin Welsch
39:57 - 40:46

Thank you everybody, and thank you to all the people that were asking questions. So, I think we are now at a very pivotal moment for the company. And obviously with the rights issue, we have the chance to deliver the most important next data point. And as I already mentioned earlier during the Q&A. So, what is important to remember is that we are developing first-in-class assets. That unfortunately takes a little bit longer and also requires more data. But I think with the rights issue, we are well equipped to tackle that and then hopefully to unlock the full value. With this, I would like to close and thank you very much for your attention.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…